PIPAC with paclitaxel for resistant ovarian cancer
Part of Cancer, Digestive system, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests a new way of giving the chemotherapy drug paclitaxel directly into the belly cavity as a spray during a short surgery (PIPAC) for women with ovarian cancer that is no longer responding to standard platinum-based chemo. It aims to see if this treatment is safe, tolerable, and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 19 and 85 years old
- You have ovarian, fallopian tube, or peritoneal cancer that is confirmed by biopsy
- Your cancer got worse during or within 6 months of platinum-based chemo
- You have had at least 2 different IV chemotherapies (you can have had paclitaxel already)
- You have at least one spot of cancer on the lining of your belly (peritoneum) visible on a scan
- You are not pregnant, use effective birth control if you could become pregnant, and have no major health problems that would make the treatment unsafe
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to deliver chemotherapy directly into the abdomen (called PIPAC) for women with advanced ovarian cancer who cannot have surgery to remove all tumors. The goal is to see if this approach is safe and helps slow cancer growth.
This trial tests a special chemotherapy delivery method called PIPAC (pressurized intraperitoneal aerosol chemotherapy) for ovarian cancer that has spread within the abdomen. The goal is to deliver cancer-fighting drugs more effectively directly to where the cancer is.
This Phase 1 study tests a new way to deliver chemotherapy inside the abdomen (belly) using a pressurized aerosol during a procedure, along with standard blood (IV) chemotherapy. It may help people with advanced ovarian cancer whose tumors have not progressed but are not removable with surgery yet.
This Phase 1 trial tests PIPAC, a way to deliver anti-cancer medicine directly into the abdomen using a minimally invasive procedure. It is for people with peritoneal spread from certain cancers to see whether this approach is safe and potentially helpful.
This trial tests a new way to deliver chemotherapy directly into the abdomen (called PIPAC) for people with cancer spread to the lining of the belly. It uses the drug mitomycin and is for patients who cannot have standard surgery or heated chemotherapy.
This trial tests a treatment called PIPAC, where chemotherapy is sprayed as a mist into the abdomen during a minimally invasive surgery. It is for people whose pancreatic cancer has spread to the lining of the belly, and aims to see if this approach is safe and helpful.
Hear when a new Ovarian Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.